Biologics for Rheumatoid Arthritis Treatment

Name
Biologics for Rheumatoid Arthritis Treatment
Accession Number
DBCAT003020
Description
Not Available
Drugs
DrugDrug Description
AbataceptA disease-modifying antirheumatic drug (DMARD) used for the management of moderate-to-severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis as monotherapy or in combination with other DMARDs.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
GolimumabA TNF╬▒ inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
TofacitinibA Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
Drugs & Drug Targets
DrugTargetType
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AdalimumabTumor necrosis factortarget
AnakinraInterleukin-1 receptor type 1target
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
GolimumabTumor necrosis factortarget
InfliximabTumor necrosis factortarget
RituximabB-lymphocyte antigen CD20target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
TofacitinibNon-receptor tyrosine-protein kinase TYK2target
TofacitinibCytochrome P450 3A4enzyme
TofacitinibCytochrome P450 2C19enzyme
TofacitinibTyrosine-protein kinase JAK2target
TofacitinibTyrosine-protein kinase JAK1target
TofacitinibTyrosine-protein kinase JAK3target
TofacitinibSerum albumincarrier
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget